Neumora Therapeutics (NMRA) Change in Accured Expenses (2022 - 2026)

Neumora Therapeutics has reported Change in Accured Expenses for 5 years, with the latest figure at -$4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 339.43% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (down 111.54% YoY), and the FY2025 full-year result was $4.2 million, down 42.03% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.0 million, down from $4.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $7.6 million in Q3 2024, with the low at -$6.3 million in Q2 2025.
• Average Change in Accured Expenses over 5 years is $1.5 million, with a median of $1.9 million recorded in 2024.
• Peak annual rise in Change in Accured Expenses reached 184.95% in 2024, while the deepest fall reached 458.83% in 2024.
• Tracing NMRA's Change in Accured Expenses over 5 years: stood at $7.0 million in 2022, then sank by 130.73% to -$2.2 million in 2023, then jumped by 184.95% to $1.8 million in 2024, then soared by 116.89% to $4.0 million in 2025, then plunged by 201.01% to -$4.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.

Peer Comparison